Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 5/20 | 0.71 |
| ▸ | CCR3 | P51677 | 3/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.58 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500525 | 0.91 | CCR8 (0.88) | CCR8CCR3SIGMAR1 | |
| SCHEMBL3599975 | 0.85 | CCR8 (0.58) | CCR8CCR3FAAH | |
| SCHEMBL3938451 | 0.83 | CHRM4 (0.65) | CCR8CCR3 | |
| SCHEMBL6499380 | 0.83 | CCR8 (1.00) | CCR8CCR3SIGMAR1 | |
| SCHEMBL6507394 | 0.82 | CCR8 (0.78) | CCR8CCR3SIGMAR1SLC6A12MCHR1 | |
| SCHEMBL17099425 | 0.81 | CCR8 (0.59) | CCR8CCR3FAAH | |
| SCHEMBL6500103 | 0.81 | CCR8 (1.00) | CCR8SIGMAR1 | |
| SCHEMBL3599977 | 0.81 | CCR3 (0.57) | CCR8CCR3FAAH | |
| SCHEMBL6509291 | 0.80 | CCR8 (0.82) | CCR8SIGMAR1MCHR1PRKAA2 | |
| SCHEMBL6498271 | 0.80 | CCR8 (0.82) | CCR8CCR3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | claimed |
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | disclosed |
| EP-1720550-A1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | Sanofi-Aventis (FR) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005089759-A1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | CCR8 2783/4885CCR3 1379/4885SIGMAR1 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.